Novavax, Inc. (NVAX) - NASDAQ
  • Nov. 20, 2014, 10:34 AM
    • The FDA grants Fast Track status to Novavax's (NVAX +2.7%) RSV F-Protein nanoparticle vaccine candidate for protection of infants via maternal immunization.
    • Fast Track designation provides for more frequent interactions with the FDA and a rolling review of the BLA submission.
    | Nov. 20, 2014, 10:34 AM | 1 Comment
  • Nov. 5, 2014, 4:32 PM
    • Novavax (NASDAQ:NVAX): Q3 EPS of -$0.08 misses by $0.01.
    • Revenue of $8.21M (+71.0% Y/Y) misses by $1M.
    | Nov. 5, 2014, 4:32 PM
  • Oct. 30, 2014, 9:18 AM
    | Oct. 30, 2014, 9:18 AM | 1 Comment
  • Oct. 27, 2014, 9:13 AM
    | Oct. 27, 2014, 9:13 AM | 1 Comment
  • Sep. 24, 2014, 4:44 PM
    • The U.S. Department of Health and Human Services' Biomedical Advanced Research and Development Authority exercises the option period on its current contract with Novavax (NVAX +0.9%) for the advanced development of its recombinant seasonal and pandemic influenza vaccines and manufacturing capabilities for pandemic preparedness.
    • The option period adds scope and funding and extends the contract until September 2016. Novavax has continued access to the remainder of the $97M base period funding (~$32M) plus an additional $70M to support development activities leading to a planned Phase 3 clinical trial in 2016.
    | Sep. 24, 2014, 4:44 PM | 5 Comments
  • Sep. 23, 2014, 9:10 AM
    | Sep. 23, 2014, 9:10 AM
  • Aug. 6, 2014, 9:21 PM
    • Novavax (NVAX +3.2%) Q2 results: Revenues: $8.3M (+133.9%); Operating Loss: ($17.9M) (-38.8%); Net Loss: ($17.9M) (-42.1%); Loss Per Share: ($0.08) (unch); Quick Assets: $208.9M (+56.9%).
    • No guidance given.
    | Aug. 6, 2014, 9:21 PM
  • Aug. 6, 2014, 4:36 PM
    • Novavax (NASDAQ:NVAX): Q2 EPS of -$0.08 misses by $0.02.
    • Revenue of $8.3M (+135.1% Y/Y) misses by $0.44M.
    | Aug. 6, 2014, 4:36 PM
  • Jun. 11, 2014, 4:19 PM
    • The underwriters of Novavax's (NVAX +1.3%) equity offering have exercised their over-allotment of 3.75M shares at $4.00. This increases the net proceeds to the company to ~$108M.
    | Jun. 11, 2014, 4:19 PM | 1 Comment
  • Jun. 6, 2014, 9:14 AM
    | Jun. 6, 2014, 9:14 AM
  • Jun. 6, 2014, 7:15 AM
    • Novavax (NVAX) prices its public offering of 25M shares of common stock at $4.00 per share. Underwriters over-allotment is 3.75M shares. Net proceeds of ~$94M will be used for general corporate purposes, the advancement of its clinical-stage vaccine candidates, its preclinical research programs, manufacturing and process development activities, CAPEX and other strategic purposes. Closing date is June 11.
    | Jun. 6, 2014, 7:15 AM
  • Jun. 5, 2014, 9:12 AM
    | Jun. 5, 2014, 9:12 AM | 1 Comment
  • Jun. 4, 2014, 5:42 PM
    • Novavax (NVAX) says it'll use the offering's proceeds for "general corporate purposes, the advancement of its clinical-stage vaccine candidates and its preclinical research programs, manufacturing and process development activities, capital expenditures and other strategic purposes."
    • The drug developer had $110.3M in cash at the end of Q1, and less than $2M in debt. 2013 free cash flow was -$51M.
    | Jun. 4, 2014, 5:42 PM | 6 Comments
  • Jun. 4, 2014, 5:33 PM
    • Top gainers, as of 5:15 p.m.: HALO +11.4%. VRNT +7.1%. RRD +4.3%. PERI +4.3%. FUEL +3.8%.
    • Top losers, as of 5:15 p.m.: NVAX -9.7%. PVH -6.5%. TSL -3.2%. GTAT -2.7%. BV -2.3%.
    | Jun. 4, 2014, 5:33 PM
  • May 7, 2014, 4:15 PM
    • Novavax (NVAX): Q1 EPS of -$0.07 in-line.
    • Revenue of $7.5M (+95.8% Y/Y) misses by $0.91M.
    | May 7, 2014, 4:15 PM
  • Apr. 29, 2014, 3:20 PM
    • Shares of Novavax (NVAX +15.2%) enjoy a modest bounce on average volume as money flow returns to the biotech sector today.
    • Yesterday, the company reported positive top-line results from its Phase 2 dose confirmation trial for its RSV vaccine. The primary endpoint was safety and immune response as measured by IgG-F antibody levels. The highest immune responses were observed in patients that received one dose of vaccine combined with aluminum phosphate adjuvant. No quantitative data were disclosed.
    • The company has requested a Type C meeting with the FDA for this summer to discuss the data and hopefully get the agency's go-ahead to proceed to a Phase 3 trial. Any FDA approval is easily two years away.
    | Apr. 29, 2014, 3:20 PM | 1 Comment
Company Description
Novavax, Inc. operates as a clinical-stage biopharmaceutical company, which engages in development of novel recombinant vaccines to address a broad range of infectious diseases. The company's technology platform is based on proprietary recombinant vaccine technology that includes virus-like... More
Sector: Healthcare
Industry: Biotechnology
Country: United States